SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-21-019170
Filing Date
2021-08-10
Accepted
2021-08-10 16:05:59
Documents
53
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1248520
2 ex31-1.htm EX-31.1 11223
3 ex31-2.htm EX-31.2 11243
4 ex32-1.htm EX-32.1 4053
5 ex32-2.htm EX-32.2 4091
  Complete submission text file 0001493152-21-019170.txt   5650940

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE lixt-20210630.xsd EX-101.SCH 43011
7 XBRL CALCULATION FILE lixt-20210630_cal.xml EX-101.CAL 31685
8 XBRL DEFINITION FILE lixt-20210630_def.xml EX-101.DEF 214864
9 XBRL LABEL FILE lixt-20210630_lab.xml EX-101.LAB 353363
10 XBRL PRESENTATION FILE lixt-20210630_pre.xml EX-101.PRE 265288
11 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 945114
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

IRS No.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39717 | Film No.: 211159897
SIC: 2834 Pharmaceutical Preparations